Company Search:
Advanced Search
Sponsored Links
Hualan Biological Engineering Inc Company Snapshot
Hualan Biological Engineering Inc operates in the Biological products exc. diagnostic sector. In addition to historical fundamental analyses, the complete report available to purchase compares Hualan Biological Engineering Inc with three other companies in this sector in China: Beijing Tiantan Biologic. (2015 sales of 1.62 billion Chinese Renmimbi [US$234.97 million] ), Staidson (Beijing) Biopharmaceuticals Co Ltd (1.25 billion Chinese Renmimbi [US$181.31 million] of which 100% was Pharmaceutical manufacturing), and Tonghua Dongbao Medicines Company Limited (1.67 billion Chinese Renmimbi [US$242.27 million] of which 97% was Pharmaceutical).

Sales Analysis. Hualan Biological Engineering Inc reported sales of 1.47 billion Chinese Renmimbi (US$213.62 million) for the year ending December of 2015. This represents an increase of 18.3% versus 2014, when the company's sales were 1.24 billion Chinese Renmimbi. This was the fourth straight year of sales growth at Hualan Biological Engineering Inc. Sales of Blood Products saw an increase of 26.4% in 2015, from 1.07 billion Chinese Renmimbi to 1.35 billion Chinese Renmimbi. Not all segments of Hualan Biological Engineering Inc experienced an increase in sales in 2015: sales of Other Operations fell 47.1% to 6.58 million Chinese Renmimbi. (However, this segment's sales were only a very small portion of the company's overall sales). Hualan Biological Engineering Inc also experienced decreases in sales in Vaccine Products (down 30.6% to 111.17 million Chinese Renmimbi) .
Company ReportsSubscriptions
Looking For More?
Purchace an In-Depth Report
Hualan Biological Engineering Inc
  Stock Performance Chart for Hualan Biological Engineering Inc
  Stock Data: Recent Stock Performance:
  Current Price (3/24/2017): 37.30
(Figures in Chinese Renmimbi)
1 Week 4.5%   13 Weeks 2.4%  
4 Weeks 6.2%   52 Weeks 40.1%  
Hualan Biological Engineering Inc Key Data:
  Ticker: 002007 Country: China
  Exchanges: SZN Major Industry: Pharmaceuticals & Biotechnology
    Sub Industry: Biological Products Exc. Diagnostic
  2015 Sales 1,470,273,674
(Year Ending Jan 2016).
Employees: 1,515
  Currency: Chinese Renmimbi Market Cap: 34,692,270,464
  Fiscal Yr Ends: December Shares Outstanding: 930,087,680
  Share Type: A Shares Closely Held Shares: 484,228,454
Sponsored Links
Feedback | Terms and Conditions | Privacy Policy | Site Index
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.